FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI
/
DateSep 12 2023
The basis for the approval was the successful results for deep-vein arterialization borne out in the PROMISE II trial. The US Food and Drug Administration... Read More →

















